4.7 Review

Targeting EphA2 in cancer

Journal

JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 13, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s13045-020-00944-9

Keywords

EphA2 receptor; Ephrin A1; Cancer; Therapy; Target

Funding

  1. National Natural Science Foundation of China [81230053, 81874132, 81802947, 81472801, 81672687]
  2. State Key Basic Research Program of China [2013CB910502]
  3. Changsha Science and Technology Board [kq1801110]
  4. Natural Science Foundation of Hunan Province [2019JJ50968]
  5. Shenzhen Science and Technology Program of China [KQTD20170810160226082]

Ask authors/readers for more resources

Eph receptors and the corresponding Eph receptor-interacting (ephrin) ligands jointly constitute a critical cell signaling network that has multiple functions. The tyrosine kinase EphA2, which belongs to the family of Eph receptors, is highly produced in tumor tissues, while found at relatively low levels in most normal adult tissues, indicating its potential application in cancer treatment. After 30 years of investigation, a large amount of data regarding EphA2 functions have been compiled. Meanwhile, several compounds targeting EphA2 have been evaluated and tested in clinical studies, albeit with limited clinical success. The present review briefly describes the contribution of EphA2-ephrin A1 signaling axis to carcinogenesis. In addition, the roles of EphA2 in resistance to molecular-targeted agents were examined. In particular, we focused on EphA2's potential as a target for cancer treatment to provide insights into the application of EphA2 targeting in anticancer strategies. Overall, EphA2 represents a potential target for treating malignant tumors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available